OMedLive

CME Presentations

Ovarian Cancer


Presentations

  • CME
    1.0

    Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics

    Speakers:Bradley J. Monk, MD, FACOG, FACS, Professor, Gynecologic Oncology
    Robert L. Coleman, MD, FACOG, FACS, Professor and Vice Chair of Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine

    Duration: 60 minutes

    Presented on: October 20, 2017


Speakers

  • Bradley J. Monk, MD, FACOG, FACS

    Bradley J. Monk, MD, FACOG, FACS

    Bradley J. Monk, MD, FACOG, FACS

    Professor, Gynecologic Oncology

    Bradley J. Monk, MD, FACS, FACOG, is professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, and a professor at the University of Arizona College of Medicine, both located in Phoenix. His clinical interests include the use of chemotherapy to treat ovarian and cervical carcinoma, etiology/biomarkers in gynecologic cancers, and quality-of-life aspects of cancer care. Dr Monk has authored more than 275 peer-reviewed articles and 31 book chapters, and is an active member of various professional organizations, such as the Society of Gynecologic Oncology and the American Society of Clinical Oncology. He earned his medical degree from the University of Arizona College of Medicine in Tucson.
  • Robert L. Coleman, MD, FACOG, FACS

    Robert L. Coleman, MD, FACOG, FACS

    Robert L. Coleman, MD, FACOG, FACS

    Professor and Vice Chair of Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine


CME Information

 

Ovarian Cancer: Enhancing Treatment with Targets and Companion Diagnostics

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT This activity is supported by independent educational grants from Clovis Oncology and AbbVie.

TUITION Complimentary

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Internet Activity The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Continuing Nursing Education Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1 contact hour(s) is provided by the Postgraduate Institute for Medicine. Pharmacy Continuing Education

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-17-L01-P) Type of Activity: Application

DATE OF RELEASE/EXPIRATION Live Activity Friday, October 20, 2017 from 10:00 – 11:00am PT. Enduring Material The enduring material will be available from October 20, 2017 to April 20, 2018

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Appraise the pathophysiology of ovarian cancer and their associated mutations, including germline and somatic BRCA mutations and other DNA repair deficiencies such as loss of heterozygosity
Evaluate the safety and efficacy data of PARP inhibitors
Use the latest diagnostic tools and genetic testing to identify patients who would benefit from PARP inhibitor therapy

TARGET AUDIENCE This activity is intended for medical and gynecologic oncologists, oncology nurses, nurse practitioners, pharmacists, and other health care professionals, including gynecologists, primary care physicians, physicians-in-training, and physician assistants involved in and/or interested in the management of patients with ovarian cancer.

ESTIMATED TIME TO COMPLETE This activity consists of one session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to http://www.OMedLive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Bradley J. Monk, MD, FACOG, FACS Professor Arizona Oncology (US Oncology Network) University of Arizona College of Medicine – Phoenix Creighton University School of Medicine at St. Joseph’s Hospital Consulting: AbbVie, Amgen, AstraZeneca, Biodesix, Clovis, Gradalis, ImmunoGen, Incyte, Insys, Mateon, Merck, Perthera, Pfizer, Precision Oncology, Roche/Genentech, Tesaro Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro Contracted Research: Pfizer
Robert L. Coleman, MD, FACOG, FACS Professor and Vice Chair of Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer Center

Consulting: AbbVie, Debiopharma, Genmab, ImmunoGen, Merrimack, Navigant Consulting, Perthera, Tesaro, Vaniam Group, LLC, Verastem Speaker: BioAscend (CME), OncLive, Roche Scientific/Advisory Board: AstraZeneca, Bayer Healthcare, Inc., Caris Life Sciences, Cerulean, Clovis Oncology,Gamamabs, Janssen, Novocure, Precision Oncology, Roche, Tesaro (GOG) Funded Research: Array Bio Pharmaceuticals, AstraZeneca, Clovis Oncology, EMD Serono, Gradalis, Janssen, Merck

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reprted Financial Relationship
Hamsa Jaganathan, PhD Medical Director PlatformQ Health Education, LLC None

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.